Carrimycin ameliorates lipopolysaccharide and cecal ligation and puncture-induced sepsis in mice

Abstract

Carrimycin (CA), sanctioned by China’s National Medical Products Administration (NMPA) in 2019 for treating acute bronchitis and sinusitis, has recently been observed to exhibit multifaceted biological activities, encompassing anti-inflammatory, antiviral, and anti-tumor properties. Despite these applications, its efficacy in sepsis treatment remains unexplored. This study introduces a novel function of CA, demonstrating its capacity to mitigate sepsis induced by lipopolysaccharide (LPS) and cecal ligation and puncture (CLP) in mice models. Our research employed in vitro assays, real-time quantitative polymerase chain reaction (RT-qPCR), and RNA-seq analysis to establish that CA significantly reduces the levels of pro-inflammatory cytokines, namely tumor necrosis factor-alpha (TNF-α), interleukin 1 beta (IL-1β), and interleukin 6 (IL-6), in response to LPS stimulation. Additionally, Western blotting and immunofluorescence assays revealed that CA impedes Nuclear Factor Kappa B (NF-κB) activation in LPS-stimulated RAW264.7 cells. Complementing these findings, in vivo experiments demonstrated that CA effectively alleviates LPS- and CLP-triggered organ inflammation in C57BL/6 mice. Further insights were gained through 16S sequencing, highlighting CA’s pivotal role in enhancing gut microbiota diversity and modulating metabolic pathways, particularly by augmenting the production of short-chain fatty acids in mice subjected to CLP. Notably, a comparative analysis revealed that CA’s anti-inflammatory efficacy surpasses that of equivalent doses of aspirin (ASP) and TIENAM. Collectively, these findings suggest that CA exhibits significant therapeutic potential in sepsis treatment. This discovery provides a foundational theoretical basis for the clinical application of CA in sepsis management.

Keywords

Carrimycin / Inflammation / Lipopolysaccharide / Cecal ligation and puncture / Sepsis / Gut microbiota

References

[1] Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3)[J]. JAMA, 2016, 315(8): 801-810.

[2] Fröhlich E. Structure and function of blood-tissue barriers[J]. Dtsch Med Wochenschr (1946), 2002, 127(49): 2629-2634.

[3] Yende S, Linde-Zwirble W, Mayr F, et al. Risk of cardiovascular events in survivors of severe sepsis[J]. Am J Respir Crit Care Med, 2014, 189(9): 1065-1074.

[4] Silasi-Mansat R, Zhu H, Popescu NI, et al. Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis[J]. Blood, 2010, 116(6): 1002-1010.

[5] Nieman MT. Protease-activated receptors in hemostasis[J]. Blood, 2016, 128(2): 169-177.

[6] Opal S, van der Poll T. Endothelial barrier dysfunction in septic shock[J]. J Intern Med, 2015, 277(3): 277-293.

[7] Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy[J]. Nat Rev Immunol, 2013, 13(12): 862-874.

[8] Pastille E, Didovic S, Brauckmann D, et al. Modulation of dendritic cell differentiation in the bone marrow mediates sustained immunosuppression after polymicrobial sepsis[J]. J Immunol, 2011, 186(2): 977-986.

[9] van der Poll T, Opal SM. Host-pathogen interactions in sepsis[J]. Lancet Infect Dis, 2008, 8(1): 32-43.

[10] Kang JH, Super M, Yung CW, et al. An extracorporeal blood-cleansing device for sepsis therapy[J]. Nat Med, 2014, 20(10): 1211-1216.

[11] Perner A, Gordon AC, De Backer D, et al. Sepsis: frontiers in diagnosis, resuscitation and antibiotic therapy[J]. Intensive Care Med, 2016, 42(12): 1958-1969.

[12] Brown RM, Semler MW. Fluid management in sepsis[J]. J Intensive Care Med, 2019, 34(5): 364-373.

[13] Leentjens J, Kox M, van der Hoeven JG, et al. Immunotherapy for the adjunctive treatment of sepsis: from immunosuppression to immunostimulation. Time for a paradigm change?[J]. Am J Respir Crit Care Med, 2013, 187(12): 1287-1293.

[14] Ferrer R, Martin-Loeches I, Phillips G, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program[J]. Crit Care Med, 2014, 42(8): 1749-1755.

[15] Roberts JA, Abdul-Aziz MH, Davis JS, et al. Continuous versus intermittent β-lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials[J]. Am J Respir Crit Care Med, 2016, 194(6): 681-691.

[16] Abdul-Aziz MH, Sulaiman H, Mat-Nor M-B, et al. β-Lactam infusion in severe sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent β-lactam infusion in critically ill patients with severe sepsis[J]. Intensive Care Med, 2016, 42(10): 1535-1545.

[17] Shang GD, Dai JL, Wang YG. Construction and physiological studies on a stable bioengineered strain of shengjimycin[J]. J Antibiot (Tokyo), 2001, 54(1): 66-73.

[18] Shi XG, Sun YM, Zhang YF, et al. Tissue distribution of bitespiramycin and spiramycin in rats[J]. Acta Pharmacol Sin, 2004, 25(11): 1396-1401.

[19] Shi XG, Fawcett JP, Chen XY, et al. Structural identification of bitespiramycin metabolites in rat: a single oral dose study[J]. Xenobiotica, 2005, 35(4): 343-358.

[20] Zhong DF, Shi XG, Sun L, et al. Determination of three major components of bitespiramycin and their major active metabolites in rat plasma by liquid chromatography-ion trap mass spectrometry[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2003, 791(1-2): 45-53.

[21] He WQ, Yang CP, Zhao XF, et al. Antimicrobial activity of bitespiramycin, a new genetically engineered macrolide[J]. Bioorg Med Chem Lett, 2017, 27(19): 4576-4577.

[22] Morgan AM, Roden RC, Matson SC, et al. Severe sepsis and acute myocardial dysfunction in an adolescent with Chlamydia trachomatis pelvic inflammatory disease: a case report[J]. J Pediatr Adolesc Gynecol, 2018, 31(2): 143-145.

[23] Rodríguez RB, Etayo BZ, Aguar RB, et al. Community-acquired pneumonia, acute respiratory distress syndrome, and severe sepsis due to Chlamydia pneumoniae[J]. Rev Clin Esp, 2002, 202(11): 623.

[24] Pinna GS, Skevaki CL, Kafetzis DA. The significance of Ureaplasma urealyticum as a pathogenic agent in the paediatric population[J]. Curr Opin Infect Dis, 2006, 19(3): 283-289.

[25] Yan HY, Sun J, Wang K, et al. Repurposing carrimycin as an antiviral agent against human coronaviruses, including the currently pandemic SARS-CoV-2[J]. Acta Pharm Sin B, 2021, 11(9): 2850-2858.

[26] Liang SY, Zhao TC, Zhou ZH, et al. Anti-tumor effect of carrimycin on oral squamous cell carcinoma cells in vitro and in vivo[J]. Transl Oncol, 2021, 14(6): 101074.

[27] Jin Y, Zuo HX, Li MY, et al. Anti-tumor effects of carrimycin and monomeric isovalerylspiramycin I on hepatocellular carcinoma in vitro andin vivo[J]. Front Pharmacol, 2021, 12: 774231.

[28] Cui J, Zhou J, He W, et al. Targeting selenoprotein H in the nucleolus suppresses tumors and metastases by isovalerylspiramycin I[J]. J Exp Clin Cancer Res, 2022, 41(1): 126.

[29] Behal ML, Nguyen JL, Li X, et al. Azithromycin and major adverse kidney events in critically Ill patients with sepsis-associated acute kidney injury[J]. Shock, 2022, 57(4): 479-485.

[30] Rittirsch D, Huber-Lang MS, Flierl MA, et al. Immunodesign of experimental sepsis by cecal ligation and puncture[J]. Nat Protoc, 2009, 4(1): 31-36.

[31] Bosmann M, Ward PA. The inflammatory response in sepsis[J]. Trends Immunol, 2013, 34(3): 129-136.

[32] Pham CG, Bubici C, Zazzeroni F, et al. Ferritin heavy chain upregulation by NF-κB inhibits TNFα-induced apoptosis by suppressing reactive oxygen species[J]. Cell, 2004, 119(4): 529-542.

[33] Lelubre C, Vincent JL. Mechanisms and treatment of organ failure in sepsis[J]. Nat Rev Nephrol, 2018, 14(7): 417-427.

[34] Park I, Kim M, Choe K, et al. Neutrophils disturb pulmonary microcirculation in sepsis-induced acute lung injury[J]. Eur Respir J, 2019, 53(3): 1800786.

[35] Dejager L, Pinheiro I, Dejonckheere E, et al. Cecal ligation and puncture: the gold standard model for polymicrobial sepsis?[J]. Trends Microbiol, 2011, 19(4): 198-208.

[36] Adelman MW, Woodworth MH, Langelier C, et al. The gut microbiome’s role in the development, maintenance, and outcomes of sepsis[J]. Crit Care, 2020, 24(1): 278.

[37] Duvallet C, Gibbons SM, Gurry T, et al. Meta-analysis of gut microbiome studies identifies disease-specific and shared responses[J]. Nat Commun, 2017, 8(1): 1784.

[38] Colbert JF, Schmidt EP, Faubel S, et al. Severe sepsis outcomes among hospitalizations with inflammatory bowel disease[J]. Shock, 2017, 47(2): 128-131.

[39] Liang H, Song H, Zhang X, et al. Metformin attenuated sepsis-related liver injury by modulating gut microbiota[J]. Emerg Microbes Infect, 2022, 11(1): 815-828.

[40] Kayagaki N, Stowe IB, Lee BL, et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling[J]. Nature, 2015, 526(7575): 666-671.

[41] Kayagaki N, Wong MT, Stowe IB, et al. Noncanonical inflammasome activation by intracellular LPS independent of TLR4[J]. Science, 2013, 341(6151): 1246-1249.

[42] Nayyar C, Thakur P, Tak V, et al. Shigella sonnei sepsis in an infant: a case report[J]. J Clin Diagn Res, 2017, 11(5): DD01-DD02.

[43] Li SX, Yu SF, Peng MF, et al. Clinical features and development of sepsis in Klebsiella pneumoniae infected liver abscess patients: a retrospective analysis of 135 cases[J]. BMC Infect Dis, 2021, 21(1): 597.

[44] Dong N, Yang XM, Chan EW, et al. Klebsiella species: Taxonomy, hypervirulence and multidrug resistance[J]. EBioMedicine, 2022, 79: 103998.

[45] Wang JK, He YT, Yu DQ, et al. Perilla oil regulates intestinal microbiota and alleviates insulin resistance through the PI3K/AKT signaling pathway in type-2 diabetic KKAy mice[J]. Food Chem Toxicol, 2020, 35: 110965.

[46] Lai HC, Lin TL, Chen TW, et al. Gut microbiota modulates COPD pathogenesis: role of anti-inflammatory Parabacteroides goldsteinii lipopolysaccharide[J]. Gut, 2022, 71(2): 309-321.

[47] Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease[J]. Nat Rev Microbiol, 2021, 19(1): 55-71.

[48] Pascale A, Marchesi N, Marelli C, et al. Microbiota and metabolic diseases[J]. Endocrine, 2018, 61(3): 357-371.

[49] Wang W, Chen L, Zhou R, et al. Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease[J]. J Clin Microbiol, 2014, 52(2): 398-406.

[50] Scher JU, Ubeda C, Artacho A, et al. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease[J]. Arthritis Rheumatol, 2015, 67(1): 128-139.

[51] Das UN. Combination of aspirin with essential fatty acids is superior to aspirin alone to prevent or ameliorate sepsis or ARDS[J]. Lipids Health Dis, 2016, 15(1): 206.

[52] Liu Y, Fang S, Li X, et al. Aspirin inhibits LPS-induced macrophage activation via the NF-κB pathway[J]. Sci Rep, 2017, 7(1): 11549.

[53] Jiang R, Wei L, Zhu M, et al. Aspirin inhibits LPS-induced expression of PI3K/Akt, ERK, NF-κB, CX3CL1, and MMPs in human bronchial epithelial cells[J]. Inflammation, 2016, 39(2): 643-650.

[54] Xie XD, Pang B. Clinical curative effect of Tienam combined with bronohoalveolar lavage on severe pneumonia and its influences on serum inflammatory indexes[J]. J North Sichuan Med College, 2021, 36(11): 1501-1507.

[55] Wang F, Zhou QY, Lu T. Imipenem cilastatin sodium/meropenem in the treatment of patients with early lung cancer complicated severe pulmonary infection[J]. Chin J Clin Res, 2022, 35(9): 1305-1309.

[56] Beltrán-García J, Osca-Verdegal R, Pallardó FV, et al. Sepsis and coronavirus disease 2019: common features and anti-inflammatory therapeutic approaches[J]. Crit Care Med, 2020, 48(12): 1841-1844.

[57] Yoshioka D, Kajiwara C, Ishii Y, et al. Efficacy of β-lactam-plus-macrolide combination therapy in a mouse model of lethal pneumococcal pneumonia[J]. Antimicrob Agents Chemother, 2016, 60(10): 6146-6154.

[58] Amado-Rodríguez L, González-López A, López-Alonso I, et al. Anti-inflammatory effects of clarithromycin in ventilator-induced lung injury[J]. Respir Res, 2013, 14(1): 1-9.

[59] Patel A, Joseph J, Periasamy H, et al. Azithromycin in combination with ceftriaxone reduces systemic inflammation and provides survival benefit in a murine model of polymicrobial sepsis[J]. Antimicrob Agents Chemother, 2018, 62(9): e00752-00718.

[60] Takeuchi O, Akira S. Pattern recognition receptors and inflammation[J]. Cell, 2010, 140(6): 805-820.

[61] van der Poll T, van de Veerdonk FL, Scicluna BP, et al. The immunopathology of sepsis and potential therapeutic targets[J]. Nat Rev Immunol, 2017, 17(7): 407-420.

[62] Jensen IJ, McGonagill PW, Butler NS, et al. NK cell-derived IL-10 supports host survival during sepsis[J]. J Immunol, 2021, 206(6): 1171-1180.

[63] Christaki E, Diza E, Giamarellos-Bourboulis EJ, et al. NK and NKT cell depletion alters the outcome of experimental pneumococcal pneumonia: relationship with regulation of interferon-γ production[J]. J Immunol Res, 2015, 2015: 532717.

[64] Greenberg AH. The origins of the NK cell, or a Canadian in King Ivan’s court[J]. Clin Invest Med, 1994, 17(6): 626-631.

[65] Haak BW, Wiersinga WJ. The role of the gut microbiota in sepsis[J]. Lancet Gastroenterol Hepatol, 2017, 2(2): 135-143.

Funding

Excellent Young Scholars Cultivation Project of Fujian Medical University Union Hospital in China(2022XH031)

National Natural Science Foundation of China(82203439)

Natural Science Foundation of Fujian Province(2022J01263)